Format

Send to

Choose Destination
Cancer Lett. 2020 Apr 1;474:127-137. doi: 10.1016/j.canlet.2020.01.021. Epub 2020 Jan 25.

Writers, readers and erasers of RNA modifications in cancer.

Author information

1
Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
2
Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain; Institucio Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain. Electronic address: mesteller@carrerasresearch.org.

Abstract

Although cancer was originally considered a disease driven only by genetic mutations, it has now been proven that it is also an epigenetic disease driven by DNA hypermethylation-associated silencing of tumor suppressor genes and aberrant histone modifications. Very recently, a third component has emerged: the so-called epitranscriptome understood as the chemical modifications of RNA that regulate and alter the activity of RNA molecules. In this regard, the study of genetic and epigenetic disruption of the RNA-modifying proteins is gaining momentum in advancing our understanding of cancer biology. Furthermore, the development of epitranscriptomic anticancer drugs could lead to new promising and unexpected therapeutic strategies for oncology in the coming years.

KEYWORDS:

Epigenetics; RNA modifications; RNA-Editing; RNA-Modifying enzymes

PMID:
31991154
DOI:
10.1016/j.canlet.2020.01.021
Free full text

Conflict of interest statement

Declaration of competing interest ME is a consultant of Ferrer International and Quimatryx. The other authors declare that they have no conflict of interest.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center